In vitro activity of terbinafine against Indian clinical isolates of Candida albicans and non-albicans using a macrodilution method

Journal de Mycologie Medicale

Volumn 16, Issue 3, 2006, Pages 119-125

  Garg, S ^b   Naidu, J ^b   Singh, S M ^a   Nawange, S R ^a   Jharia, N ^a   Saxena, M ^b  

^a RANI DURGAVATI UNIVERSITY   (India)

^b GOVERNMENT SCIENCE COLLEGE   (India)

Author keywords

Antifungal susceptibility; Candida; Macrodilution method; Terbinafine

Indexed keywords

AMFOCAN; AMPHOTERICIN; CANDISTAT; FLUCONAZOLE; FLUSTAN; ITRACONAZOLE; KETOCONAZOLE; NIZRAL; TERBINAFINE;

ANTIFUNGAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATE; BLOOD ANALYSIS; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA GUILLIERMONDII; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CONTROLLED STUDY; DIABETES MELLITUS; DILUTION; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; IC 50; IMMUNE DEFICIENCY; IN VITRO STUDY; INOCULATION; ISOLATION PROCEDURE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OROPHARYNX CANDIDIASIS; PH MEASUREMENT; SAMPLING; SPUTUM ANALYSIS; STATISTICAL SIGNIFICANCE; TUBERCULOSIS; URINALYSIS; VAGINA CANDIDIASIS; YEAST;

ARTHRODERMATACEAE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS;

EID: 33749061308     PISSN: 11565233     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mycmed.2006.07.004     Document Type: Article

References (37)

1. Barchiesi F., and Scalise G. In vitro activities of terbinafine in combination with fluconazole and itraconazole against Candida albicans with reduced susceptibility to azoles. Antimicrob. Agents Chemother. 41 (1997) 1812-1814
2. Canton E., Peman J., Gobernado M., Viudes A., and Espinel-Ingroff A. Synergy activities of fluconazole and voriconazole with terbinafine against four Candida species determined by Checkboard, Time-kill and Etest Methods. Antimicrob. Agents Chemother. 49 (2005) 1593-1596
3. Cuenca-Estrella M. Combination of antifungal agents in therapy-what value are they?. J. Antimicrob. Agents Chemother. 54 (2004) 854-869
4. Edmond M.B., Wallace S.E., and Mc Clish D.K. Nosocomial blood stream infection in United States hospitals, 3-year analysis. Clin. Infect. Dis. 29 (1999) 239-244
5. Eiteon Abu H.K., and Eikarmi A.Z. Isolation and characterization of Candida species in Jordian cancer patients; prevalence, pathogenic determinants and antifungal sensitivity. Jpn. J. Infect. Dis. 57 (2004) 279-284
6. Faergemann J., Zehender H., and Denoucl J. Level of terbinafine in plasma, stratum Corneum, Dermis, Epidermis, Sebum, hairs and nails during and after 200 mg terbinafine one/day for 4 weeks. Acta Derm. Venereol. 73 (1993) 305-309
7. Gabor P., Josef G., and Hubet M. Antifungal activity of the allylamine derivative terbinafine in vitro. Antimicrob. Agents Chemother. 31 (1987) 1365-1368
8. Ghannoum M.A., and Elewski B. Successful treatment of fluconazole resistant OPC by a combination of fluconazole and terbinafine. Clin. Diagn. Lab. Immumol 6 (1999) 921-923
9. Govdard M.Y., Buffard H., and Ferrai P.R. In vitro spectrum of action of new antifungal derivative of notified; terbinafine (SF 86-327). Pathol. Biol. 34 (1986) 680-683
10. Hay R.J. Therapeutic potential of terbinafine in subeutaneous and systemic mycosis. Br. J. Dermatol. 41 (1999) 36
11. Hazen K.C. Fungicidal versus fungistatic activity of terbinafine and itraconazole; an in vitro comparison. J. Am. Acad. Dermatol. 38 (1998) 37-41
12. Hiratani T., Asagi Y., and Yamguchi H. Evaluation of in vitro antimycotic activity of terbinafine, a new allylamine agent. Jpn. J. Med. Mycol. 32 (1991) 323-332
13. Johnson M.D., MacDougall C., Ostrosky-Zeichner L., Perfect J.R., and Rex J.H. Combination antifungal therapy. Antimicrob. Agents Chemother. 48 (2004) 693-715
14. Luna B., Drew R.H., and Perect J.R. Agents for treatment of invasive fungal infections. Otolaryng. Clin. N. Am. 33 (2000) 277-299
15. Cuenca-Estrella M. Combination of antifungal agents in therapy what value are they?. J. Antimicrob. Agents Chemother. 54 (2004) 854-869
16. Mukherjee P.K., Sheehan D.J., Hitchcock C.A., and Ghannoum M.A. Combination treatment of invasive fungal infections. Clin. Microbiol. Rev. 18 (2005) 163-194
17. National Committee for clinical Laboratory Standard (NCCLS). Refrence method for Broth dilution antifungal susceptibility testing of yeasts (M 27-A) (1997), Approved Standards, Wayne, PA
18. Nguyen M.H., and Clanes C.J. Do in vitro susceptibility data predict the microbiologic response to Amp. B? Results of a prospective study of patients with Candida fungirmia. J. Infect. Dis. 177 (1998) 425-430
19. Perez A. Terbinafine: a blood new spectrums of indication in several subcutaneous and systemic and parasitic disease. Mycoses 42 (1999) 111-114
20. Pfaller M.A., Espinel Ingroff A., and Rex J.H. Quality control guidelines for NCCLS recommended broth macrodilution testing of Amp. B, fluconazole and flucytosine. J. Clin. Microbiol. (1995) 1104-1107
21. Pfaller M.A., Rinaldi M.C., and Bartlett M.S. Multicenter evaluation of 4 methods of yeast inoculum preparation. J. Clin. Microbiol. 26 (1988) 1437-1441
22. Pfaller M.A., and Diekewa D.J. The role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J. Clin. Microbiol. 40 (2002) 3551-3557
23. Rex J.H., and Pfaller M.A. Quality control guidelines for NCCLS recommended broth macrodilution testing of ketoconazole and itraconazole. J. Clin. Microbiol. (1996) 816-817
24. Rex J.H., Pfaller M.A., Galgiani J.N., and NCCLS. Development of interpretative break points for antifungal susceptibility testing conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole and Candida infection. Clin. Infect. Dis. 24 (1997) 235-247
25. Rodriquez-Tudela J.L., and Martinez-suarex J.V. Correlation of in vitro susceptibility test results with in vivo response; a study of azole therapy in AIDS patients J. Antimicrob. Agents Chemother. 35 (1995) 793-804
26. Rothe A., Seibolel M., and Cornely O.A. Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B. Ann. Hematol. 83 (2004) 394-397
27. Rubio M.C., Gil J., Rezusta A., and Bueno M.R. In vitro evaluation of 3 new antifungal agents: amorlfine (RO 14-4767/002), terbinafine (SF 86-327) and itraconazole (R 51-211). Rev. Esp. Quimioterap. 8 (1993) 125-139
28. Ryder N.S., and Dupont M.C. Inhibition of squalene epoxidase by allylamine antimycotic compounds: a comparative study of the fungal and mammalian enzymes. Biochem. J. 230 (1985) 765-770
29. Ryder N.S. Specific inhibition of fungal sterol biosynthesis by SF 86-327, a new allylamine antifungal agent. Antimicrob. Agents Chemother. 27 (1985) 252-256
30. Ryder N.S., and Favre B. Antifungal activity and mechanism of action of terbinafine. Rev. Comp. Pharmacother. 8 (1997) 275-287
31. Ryder N.S., and Mieth H. Allylamine antifungal drugs. Curr. Top. Med. Mycol. 4 (1992) 158-188
32. Ryder N.S., and Wayner S. In virto activities of terbinafine against cutaneous isolates of C. albicans and other pathogenic fungi. Antimicrob. Agents Chemother. 42 (1998) 1057-1061
33. Saurla Z., and Yardeni M. Species distribution of antifungal susceptibility of Candida blood stream isolates in a tertiary medical center in Israel. Eur. J. Clin. Microbiol. Infect. Dis. 24 (2005) 592-595
34. Shadomy S., Espinell Ingroff A., and Gebhart R.J. In vitro studies with SF 86-327; a new orally active allylamine derivative. Sabouraudia 23 (1985) 125-132
35. Sofia P., Gloria G., and Rinald M.G. In vitro activities of terbinafine incombination with fluconazole, itraconazole, voriconazole and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles. J. Clin. Microbiol. 40 (2002) 1831-1833
36. Stutz A., and Petranyl G. Synthesis and antifungal activity of (E)-N-(6-6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-napthalene-methanamine (SF 86-327) and related allylamine derivatives with enhanced oral activity. J. Med. Chem. 27 (1984) 1539-1543
37. Zaias N. Candida: a review of clinical experience with Lamisil (R). Dermatology 194 Suppl 1 (1997) 10-13